Here are three more details the drugmaker revealed Nov. 2 in its third-quarter earnings report.
- Pfizer’s third-quarter sales revenue totaled $24.1 billion, primarily driven by sales of the drugmaker’s COVID-19 vaccine.
- Revenue from sales of Pfizer’s COVID-19 vaccine totaled $13 billion in the third quarter.
- More than 75 percent of the vaccine’s sales in 2021 are from outside the U.S.
